Chinese architectural technology firm RoboticPlus.AI has secured $20 million in a Series B round, while newly-founded drugmaker Innolake Biopharm has closed 300 million yuan ($45.8 million) in a pre-Series A round.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
